SecBot SecBot
SECBOTREPLAY Home › Report › RVTY

RVTY · Revvity reported Q2 2026 adjusted EPS of $1.41, a 19.5% beat vs the…

REVVITY, INC. · 8-K filed Aug 4, 2026 at 06:20 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 4, 2026 at 06:20 ET

Revvity reported Q2 2026 adjusted EPS of $1.41, a 19.5% beat vs the $1.22 consensus, on revenue of $730M (above $703.2M consensus). The company raised full-year 2026 pro forma adjusted EPS guidance to $5.30-$5.40 and revenue guidance to $2.83-$2.86B, citing strong Diagnostics segment growth (+11% pro forma organic) and tariff refunds. The filing also confirms a definitive agreement to divest the China Immunodiagnostics business for up to $200M, expected to close by end of 2027. The combination of a significant earnings beat, raised guidance, and portfolio simplification is a clear positive catalyst.

  • Adjusted EPS from continuing operations of $1.41 vs consensus $1.22 (beat by +15.9%)
  • Revenue of $730M vs consensus $703.2M (beat by +3.8%)
  • Raised FY2026 guidance: pro forma adjusted EPS to $5.30-$5.40 (from $5.20-$5.30) and revenue to $2.83-$2.86B (from $2.81-$2.84B)
  • Diagnostics segment pro forma organic revenue grew 11% YoY; Life Sciences pro forma organic revenue declined 3%

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access